期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 31, 期 6, 页码 1045-1053出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-011-9589-4
关键词
Siglec-8; eosinophils; mast cells; basophils; expression; hematologic malignancies; cell lines
类别
资金
- NCRR NIH HHS [UL1 RR029879, UL1RR029879] Funding Source: Medline
- NHLBI NIH HHS [P01 HL107151] Funding Source: Medline
- NIAID NIH HHS [R01 AI072265-05, AI72265, AI41472, R01 AI072265, R21 AI041472, R01 AI041472, R56 AI072265] Funding Source: Medline
- Wellcome Trust [081882] Funding Source: Medline
The aim of this study is to determine when during hematopoiesis Siglec-8 gets expressed, whether it is expressed on hematologic malignancies, and if there are other non-human species that express Siglec-8. Siglec-8 mRNA and cell surface expression was monitored during in vitro maturation of human eosinophils and mast cells. Flow cytometry was performed on human blood and bone marrow samples, and on blood samples from dogs, baboons, and rhesus and cynomolgus monkeys. Siglec-8 is a late maturation marker. It is detectable on eosinophils and basophils from subjects with chronic eosinophilic leukemia, chronic myelogenous leukemia, and on malignant and non-malignant bone marrow mast cells, as well as the HMC-1.2 cell line. None of the Siglec-8 monoclonal antibodies tested recognized leukocytes from dogs, baboons, and rhesus and cynomolgus monkeys. Siglec-8-based therapies should not target immature human leukocytes but should recognize mature and malignant eosinophils, mast cells, and basophils. So far, there is no suitable species for preclinical testing of Siglec-8 monoclonal antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据